ICU Medical (ICUI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.2B

Revenue (quarter)

$551.7M

Revenue growth (year over year)

+0.51%

Gross profit (trailing twelve months)

$845.1M

Gross margin

39.13%

Net income (trailing twelve months)

$30.1M

Net income (quarter)

$19.1M

Net income growth (year over year)

−45.99%

Net margin

1.39%

Return on equity

1.41%

EPS (trailing twelve months)

$1.20

Book value per share

$86.05

P/E (trailing twelve months)

135.21

Price to book

1.89

Debt to assets

45.81%

Payout ratio

—

Dividend yield

—

Company profile

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

• Is ICU Medical (ICUI) profitable?

  Yes. ICU Medical earned $30.1M in net income over the trailing twelve months, a net margin of 1.39%.

• How much revenue does ICU Medical (ICUI) make?

  ICU Medical generated $2.2B in revenue over the trailing twelve months, up 0.51% year over year.

• What is ICUI's P/E ratio?

  ICU Medical trades at 135.2 times trailing twelve-month earnings, on an EPS of $1.20.

• How do I buy stock in ICU Medical (ICUI)?

  ICUI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.